Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
Medtronic plc reported a routine insider transaction by one of its executives. The officer, listed as EVP & President Neuroscience, had 439 ordinary shares withheld on 12/15/2025 to pay taxes due when previously granted restricted stock units vested, at a price of $99.87 per share.
After this tax-withholding transaction, the reporting person directly owns 54,749 Medtronic ordinary shares. This total includes 251 shares that were acquired through dividend reinvestment since the prior report.
Medtronic executive insider reported a routine tax-related share withholding. On 12/15/2025, the company’s EVP, President MedSurg and Americas had 1,371 ordinary shares withheld at $99.87 per share to cover taxes when previously reported restricted stock units vested due to retirement eligibility. After this transaction, the executive beneficially owns 50,818 Medtronic shares, including 250 shares acquired through dividend reinvestment since the last report, all held directly.
Medtronic plc reported that its Chairman and CEO, who also serves as a director, had 1,564 ordinary shares withheld on 12/15/2025 to cover taxes due upon the vesting of previously granted restricted stock units. The transaction was coded as an “F” event and recorded at a price of $99.87 per share, indicating a tax-related withholding rather than an open-market sale. After this transaction, the reporting person beneficially owns 246,393 ordinary shares directly, which includes 832 shares acquired through dividend reinvestment since the prior report.
Medtronic plc executive reports routine tax-related share withholding. The EVP & President Cardiovascular of Medtronic plc reported a transaction dated 12/05/2025 involving 1,702 ordinary shares of Medtronic. The shares were withheld to cover taxes upon the vesting of previously granted restricted stock units, a common administrative step when equity awards vest. The transaction price listed was $101.36 per share.
After this withholding, the executive beneficially owns 34,177 Medtronic ordinary shares in direct form, which includes 264 shares acquired through dividend reinvestment since the prior report. No derivative securities transactions were reported in this filing.
The Vanguard Group has updated its ownership disclosure for Medtronic PLC. The firm reports beneficial ownership of 130,949,305 shares of Medtronic common stock, representing 10.21% of the class. Vanguard reports no sole voting power over these shares, with shared voting power over 7,668,852 shares. It has sole dispositive power over 118,346,690 shares and shared dispositive power over 12,602,615 shares.
The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Medtronic. Vanguard indicates that its clients, including registered investment companies and other managed accounts, have the right to receive dividends or sale proceeds from these securities, and no single other person has an interest in more than 5% of the class.
Medtronic plc reported higher results for the quarter ended October 24, 2025. Net sales rose to $8,961 million from $8,403 million a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, with segment sales reaching $8,926 million. Net income attributable to Medtronic increased to $1,374 million from $1,270 million, and diluted earnings per share improved to $1.07 from $0.99.
For the first six months of fiscal 2026, net sales were $17,539 million versus $16,318 million, and net income attributable to Medtronic was $2,414 million compared with $2,312 million. Operating cash flow was $2,013 million, while the company continued returning cash via dividends of $1,820 million and share repurchases of $495 million. Medtronic reduced its Italian payback accrual by $39 million, recorded as a sales benefit, and recognized a $90 million fair value loss on its Mozarc Medical investment.
On the balance sheet, cash and cash equivalents stood at $1,282 million with $7,045 million in investments. Total assets were $91,346 million, total liabilities $42,489 million, and total equity $48,857 million. Long-term debt increased to $27,680 million, including new 2.950% notes due 2031 and 4.200% notes due 2046, and the company had $1.4 billion of commercial paper outstanding.
Medtronic plc (MDT) reported an insider transaction by its Chief Accounting Officer. On 11/20/2025, the officer disposed of 170 ordinary shares of Medtronic stock at a reported price of $0, which is consistent with a coded gift transaction. After this transaction, the officer beneficially owned 12,357 ordinary shares.
A footnote explains that this ownership total includes 99 shares acquired through dividend reinvestment since the prior report. The filing shows no derivative securities positions for this reporting person.
Medtronic plc executive vice president for Global Operations & Supply Chain reported multiple open-market sales of company ordinary shares. On 11/19/2025, the officer sold several blocks of Medtronic stock at prices around $102 per share, reducing but not eliminating their direct stake. Following these transactions, the officer directly owned 46,016 ordinary shares.
The reported holdings also include 323 shares acquired through dividend reinvestment and 96 shares acquired under Medtronic's Employee Stock Ownership Plan since the prior report, showing ongoing participation in company equity programs alongside the sales.
A Medtronic (MDT) shareholder filed a Form 144 notice to potentially sell 30,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate aggregate market value of $3,058,452.26. The planned sale date listed is 11/19/2025. The shares come from multiple acquisitions between 2022 and 2025, including employee stock purchase plan buys funded with cash and restricted stock units that vested as compensation. The filing also notes that Medtronic has 1,282,685,882 shares of this class outstanding, giving context for the size of the potential sale relative to the overall share count.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
